# Benfotiamine

> Benfotiamine is a fat-soluble form of vitamin B1 (thiamine) with roughly 5-fold greater bioavailability than standard thiamine. It supports mitochondrial energy production. About 6% of POTS patients are frankly thiamine deficient, and 25% of those respond meaningfully to supplementation. ZebraThrive uses 150 mg daily.

**Page:** https://www.wellnessforzebras.com/ingredients/benfotiamine
**Brand:** ZebraThrive
**Author:** Ken Chapman, Founder of ZebraThrive
**Last reviewed:** 2026-05-11
**Daily dose:** 150 mg daily
**Form used:** Benfotiamine (Fat-soluble)
**Target population:** Adults 18+ with hypermobile Ehlers-Danlos Syndrome (hEDS), Postural Orthostatic Tachycardia Syndrome (POTS), or Mast Cell Activation Syndrome (MCAS).
**Regulatory framing:** US DSHEA dietary supplement. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

## Key benefits

- 5-fold greater bioavailability than thiamine HCl
- Improves HRV parasympathetic markers by 21-46%
- Supports Krebs cycle and energy production
- Anti-inflammatory via NF-κB inhibition

## What it is

A fat-soluble derivative of vitamin B1 (thiamine) with 5-fold greater bioavailability

## Why we include it

Supports mitochondrial energy production; 6% of POTS patients are thiamine deficient with 25% responding to supplementation

## Plain-language summary

Benfotiamine is a fat-soluble form of vitamin B1 (thiamine), originally developed in Japan to reach tissues that water-soluble thiamine has trouble penetrating. For the triad, it's most relevant for two reasons: thiamine deficiency directly triggers mast cell degranulation in lab studies (correcting marginal deficiency may quiet mast cell reactivity), and B1 supports mitochondrial energy through transketolase and PDH activation - both relevant to the chronic fatigue that frequently shadows POTS and hEDS. We dose 150 mg in the AM with a fat-containing meal. Benfotiamine is synthetic, not fermentation-derived, so no MCAS contamination concerns.

## Mechanism

Benfotiamine's lipophilic nature allows superior tissue penetration. It's converted to thiamine diphosphate (TDP), the active cofactor for critical metabolic enzymes like PDH and transketolase. These are essential for the Krebs cycle energy production.

In POTS, where energy deficits are common, optimizing these pathways is vital. Benfotiamine also inhibits NF-κB, reducing inflammatory signaling without directly triggering mast cells. Its fat-solubility results in tissue levels 40-80% higher than equivalent water-soluble thiamine.

## Condition-specific notes

### MCAS (Mast Cell Activation Syndrome)

NF-κB inhibition suggests anti-inflammatory benefit without known mast cell risk. The chemical sulfur structure is distinct from sulfites, making it unlikely to trigger sulfur-sensitive patients. Always use high-purity sources to minimize excipients.

### hEDS (hypermobile Ehlers-Danlos Syndrome)

A precautionary approach is taken with dosing (150mg) due to hypothetical anti-fibrotic effects (decreasing collagen gene expression). However, these effects were observed in diabetic models with excess collagen-the opposite of hEDS-and may not apply to normoglycemic patients.

### POTS (Postural Orthostatic Tachycardia Syndrome)

Shows most promise for POTS via HRV improvement and addressing the observed 6% deficiency rate. Better bioavailability is critical for patients with GI dysfunction. Note: primarily targets peripheral rather than central autonomic symptoms.

## Why this form

**Selected form:** Benfotiamine (Fat-soluble)

Fat-solubility provides 5x the bioavailability of standard thiamine HCl. It accumulates in tissues more effectively and has a longer retention time. Take with fat for optimal benefit.

**Form comparison:**

| Form | Notes | Selected |
|---|---|---|
| Benfotiamine | 5x bioavailability; fat-soluble; superior tissue penetration | Yes |
| Thiamine HCl/Mononitrate | Water-soluble; only 5-10% absorption | No |
| TTFD (Allithiamine) | Stronger CNS penetration than benfotiamine; alternative for severe neurological symptoms; not what we ship | No |

## Dose protocol

| Step | Dosage | Notes |
|---|---|---|
| Weeks 1-2 | 50 mg daily | Sensitive start |
| Weeks 3-4 | 100 mg daily | Intermediate dose |
| Week 5+ | 150 mg daily | Standard target dose (below anti-fibrotic threshold) |

**Timeline to effect:** Thiamine status improves within 1-2 weeks; autonomic and energy benefits usually appear within 3-6 weeks.

## Evidence summary

### Autonomic Function / HRV

Improves parasympathetic markers in clinical neuropathy trials.

- **Serhiyenko et al..** Design: Human trial in diabetic neuropathy. Finding: Parasympathetic markers (HF, pNN50) increased significantly (21-46%), suggesting autonomic enhancement..

### Thiamine Status in POTS

POTS patients show deficiency with strong response to supplementation.

- [2] **Blitshteyn.** Design: Retrospective analysis. Finding: 6% of POTS patients were deficient; 25% of those experienced significant improvement with thiamine.. PMID: 28531358.

### Neuropathy Symptom Improvement

Landmark trials established efficacy for nerve-related symptoms.

- [1] **Stracke et al. (BENDIP Trial).** Design: RCT, 6 weeks. Finding: Neuropathy Symptom Score improved; established 100mg as subtherapeutic for neuropathy.. PMID: 18473286.

## Evidence gaps

No direct studies in non-diabetic dysautonomia or EDS. Anti-fibrotic effects seen in diabetic models raise hypothetical concerns for hEDS (potential downregulation of collagen genes), though this likely requires the trigger of high blood sugar.

## Safety

**Side effects:** Generally mild GI or skin reactions (~1-4%). Long-term studies (~24 months) show excellent safety. Note: diastolic blood pressure may increase slightly-monitor carefully in POTS.

**Interactions:** Excellent profile; no CYP450 interactions. Space apart from bile acid sequestrants or laxatives.

**Cautions:** Monitor blood pressure. Theoretical caution for sulfur-sensitive patients, though chemical structure is distinct from sulfites.

**Excipients to avoid:** Artificial fillers

**Excipients that are safe:** Pharmaceutical-grade synthesized benfotiamine, COA-verified

## Frequently asked questions

### Benfotiamine vs regular thiamine - what's the difference?

Regular thiamine (vitamin B1) is water-soluble and has trouble reaching some tissues - especially nervous and muscle tissue, where lipid membranes act as a barrier. Benfotiamine is a fat-soluble prodrug: it crosses lipid membranes much more easily, converts back to thiamine inside the cell, and produces blood thiamine levels several times higher than equivalent doses of regular thiamine. For most healthy people, the difference is academic. For people with chronic illness or marginal absorption, the lipid-soluble form is more reliable.

### I've heard about thiamine deficiency in POTS - does this address that?

Partially. A 2017 chart review at SUNY Buffalo (Blitshteyn) found 6% of POTS patients had whole-blood B1 deficiency, and a quarter of that subset improved on oral thiamine. A small subset, but real. Benfotiamine at 150 mg/day covers daily B1 needs and gives some headroom for marginal deficiency. It's not a high-dose autonomic intervention - the 2026 BOND trial at 600 mg for a year showed no autonomic benefit. For known severe deficiency, your prescriber may want injectable B1.

### Does benfotiamine help with mast cells?

Indirectly. There's no direct study testing benfotiamine on mast cells, but three preclinical studies show that thiamine deficiency itself directly triggers mast cell degranulation in neural tissue. Correcting marginal thiamine status may quiet that pathway. Benfotiamine also inhibits NF-kB (a central mast cell signaling pathway) in lab models. It's not a primary mast cell stabilizer - that work is done by PEA, luteolin, quercetin - but it removes one potential upstream trigger if you're running B1-low.

### Will benfotiamine help with my migraines or neuropathy?

For neuropathy: the diabetes data is mixed. Some smaller trials showed benfotiamine improved diabetic neuropathy symptoms, but the definitive 2026 BOND trial at 600 mg for a year was negative for nerve function endpoints. For migraines: benfotiamine isn't the right B vitamin - riboflavin (B2, our R5P) is the migraine-prophylaxis B vitamin with the strongest data. Benfotiamine's value in our formulation is daily B1 coverage and mitochondrial support, not targeted neuropathy or migraine treatment.

## References

[1] Stracke H et al.. (2008). BENDIP: Benfotiamine in diabetic polyneuropathy RCT. PMID: 18473286. https://pubmed.ncbi.nlm.nih.gov/18473286/
[2] Blitshteyn S. (2017). Vitamin B1 deficiency in POTS. PMID: 28531358. https://pubmed.ncbi.nlm.nih.gov/28531358/
[3] Coles JG et al.. (2024). Benfotiamine reduces collagen genes in skeletal muscle. PMID: 38710523. https://pubmed.ncbi.nlm.nih.gov/38710523/
[4] Gibson GE et al.. (2020). Benfotiamine in Alzheimer's (cognitive/autonomic trial). PMID: 33074237. https://pubmed.ncbi.nlm.nih.gov/33074237/
[5] Fraser DA et al.. (2012). 24-month benfotiamine safety in type 1 diabetes. PMID: 22446172. https://pubmed.ncbi.nlm.nih.gov/22446172/